Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 3/20 | 0.55 |
| ▸ | PDE4A | P27815 | 7/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.48 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
| ▸ | DRD2 | P14416 | 1/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.43 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | PIM1 | P11309 | 1/20 | 0.42 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.42 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.42 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16799485 | 1.00 | HTR2C (0.55) | HTR2CPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1410448 | 0.84 | PDE4A (0.45) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL8352445 | 0.81 | TSHR (0.53) | HTR2CPDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1268440 | 0.80 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL427827 | 0.79 | HTR2C (0.58) | HTR2CHTR1AHTR2AHTR2BDRD2 | |
| SCHEMBL24007592 | 0.78 | PDE4A (0.40) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL18051413 | 0.78 | PDE4A (0.43) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL17729642 | 0.77 | HTR2C (0.70) | HTR2CHTR1AHTR2AHTR2BDRD2 | |
| SCHEMBL11101873 | 0.76 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4DALDH1A1 | |
| SCHEMBL20475360 | 0.76 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4DALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3077374-A1 | PYRROLIDINONES AS HERBICIDES | E. I. du Pont de Nemours and Company (US) | 2016-10-12 | — | — | EP | disclosed |
| WO-2015084796-A1 | PYRROLIDINONES AS HERBICIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2015-06-11 | — | — | WO | disclosed |
| US-20110039893-A1 | GSK-3BETA INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-02-17 | — | — | US | disclosed |
| US-20110039893-A1 | GSK-3BETA INHIBITOR | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-02-17 | — | — | US | disclosed |
| CN-101801961-A | Pyrrolidone, tetramethyleneimine-2,5-diketone, tetramethyleneimine and thiosuccimide derivative, composition and treatment method for cancer | ARQULE INC | 2010-08-11 | — | — | CN | disclosed |
| US-5861416-A | TREATMENT OF ASTHMA OR COUGH | MERRELL PHARMACEUTICALS INC. (US) | 1999-01-19 | — | — | US | disclosed |
| US-5824690-A | TREATING ASTHMA, COUGH | HOECHST MARION ROUSSEL INC. (US) | 1998-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039893-A1 | GSK-3BETA INHIBITOR | GSK3B, GSK3A, GSKIP | HTR2C 2811/4885PDE4A 639/4885PDE4B 686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.